ストックスクリーナーアプリを入手
191.69
1.87%
3.7299
Illumina Inc (ILMN) 最新ニュース
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences - Investing News Network
Standard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm - Stock Titan
Standard BioTools Sells Mass Cytometry Unit for $5 Million Note and Nets $30 Million From Illumina - TradingView
(ILMN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Illumina Inc. stock underperforms Monday when compared to competitors - MarketWatch
ILMN|Illumina Inc|Price:189.380|Chg%:-4.710 - TradingKey
Illumina Inc (ILMN) Income Statement - TradingKey
ILMN|Illumina Inc|Price:194.090|Chg%:-2.770 - TradingKey
Illumina Inc (ILMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Illumina stock trades steady as investors weigh restructuring and recovery prospects - Ad-hoc-news.de
Illumina, Inc. Revenue Breakdown – BIVA:ILMN - TradingView
Illumina Inc (ILMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina, Inc. Revenue Breakdown – BOATS:ILMN - TradingView
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Illumina (ILMN) - The Globe and Mail
Illumina Inc (ILMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ILMN5150650 Bond Profile — Key Metrics - TradingView
Illumina stock trades steady as investors weigh Q1 2026 recovery and gene sequencing demand - Ad-hoc-news.de
Illumina stock hits 52-week high at 197.49 USD By Investing.com - Investing.com Australia
Illumina stock hits 52-week high at 197.49 USD - Investing.com UK
Illumina Inc (ILMN) Shares Surge 3.1% -- What GF Score of 72 Tel - GuruFocus
Illumina Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
ILMN6231083 Bond Profile — Key Metrics - TradingView
Illumina stock surges 90% after InvestingPro Fair Value spotted opportunity By Investing.com - Investing.com
ILMN|Illumina Inc|Price:197.110|Chg%:+0.250 - TradingKey
Illumina stock holds after a 2025 revenue rebound - Ad-hoc-news.de
Illumina stock trades steady as investors weigh Q1 2026 revenue decline and cost-cutting plan - Ad-hoc-news.de
Is Illumina Inc (ILMN) Overvalued After 4.2% Rally? GF Value Say - GuruFocus
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Lobbying Update: $300,000 of ILLUMINA INC. lobbying was just disclosed - Quiver Quantitative
Geraldine Bliss wants parents to ask, “Could it be genetic?” - Illumina
Illumina stock holds as investors await the next report - Ad-hoc-news.de
Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI - Yahoo Finance
ILUB Bond Profile — Key Metrics - TradingView
Illumina stock edges higher as investors weigh Q1 2026 results and genomics demand - Ad-hoc-news.de
Wall Street Just Pushed Illumina Targets to $200. Here’s Where the Stock Could Go - TIKR.com
Illumina stock steadies as investors weigh going concern warning and turnaround plan - ad-hoc-news.de
Illumina stock trades on earnings context after recent guidance - ad-hoc-news.de
Illumina (ILMN) Expands Billion Cell Atlas Alliance With New AI Drug Discovery Members - Sahm
Illumina expands Billion Cell Atlas alliance with Formation Bio, adds two other AI drug developers - Bitget
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors - Illumina
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution - Illumina
Illumina (ILMN) Faces German Recall Order Over Element Sequencing Patent Ruling - Yahoo Finance
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Illumina expands Billion Cell Atlas program with new AI drug dev - GuruFocus
Illumina expands Billion Cell Atlas program with new AI drug developers - marketscreener.com
Juno Bio Opens First CLIA-Certified Sequencing Lab Dedicated Entirely to Women's Health, Backed by Ada Ventures, Artesian, Illumina Accelerator, and Entrepreneur First - PR Newswire
Illumina appoints new commercial and legal officers By Investing.com - Investing.com Nigeria
Illumina price tries to gather positive momentumForecast today16-07-2026 - Economies.com
(ILMN) Risk Channels and Responsive Allocation - Stock Traders Daily
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Illumina Inc : TD Cowen Raises Target Price t - Moomoo
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - AOL.com
ILMN5886317 Bond Profile — Key Metrics - TradingView
Video: Illumina gets behind the wheel to drive greater results - Illumina
Element Biosciences Prevails in German Patent Case Against Illumina - Business Wire
Illumina, Inc. Stock 12‑Month Price Target Raised to $165.72, Implies 13% Downside - TradingView
Bioinformatics Services Market Set for Strong Growth Driven - openPR.com
Illumina, Inc. Stock 12‑Month Price Target Raised to $162.94, Implies 14% Downside - TradingView
Illumina builds out C-suite with 2 new execs - MedTech Dive
Illumina Inc (ILMN) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Illumina sets July 30 call on second-quarter 2026 results - Stock Titan
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 - marketscreener.com
0.04%
0.06%
大文字化:
|
ボリューム (24 時間):